Contrary to the perception that drug research is mostly focused on the diseases of the elite, the antimalarial drug pipeline has increased nearly three-fold since 2008, with at least three new medicines expected to be launched in two to five years.
HealthClub
India, where a lot of clinical trials have already begun, is likely to get a breakthrough anti-malarial drug Tafenoquine by 2018.
The drug, a one-day two-dose treatment, has already entered phase-three trials and once approved will replace the current 14-day treatment for plasmodium vivax malaria, which is prevalent in India.
The overall research pipeline for anti-malaria drugs has grown from a mere 17 projects in 2008 to 46 in 2016 so far. The development is driven by increased funding towards anti-malaria programmes worldwide over the last decade.
Livemint
Spending on malaria rose to $2.7 billion annually in 2015 from $130 million in 2000. Investment towards drug R&D alone has grown from $4 million in 1999 to over $750 million by end of 2015. Africa, South America and countries in Southeast Asia are also likely to witness several antimalarial drug launches over the next five years.
While the Gates Foundation has been leading the drive to eradicate malaria from the world and has set 2040 as its deadline, it has partnered various other public health organisations. "While malaria is preventable and treatable, eradication requires new tools and has changed the way the foundation views product development," says Culpepper.
Drugs India
"There is a need to work very hard to reduce the timeline for regulatory approval, pre-qualification ¡ª that is going to define how we achieve the 2040 timeline for an eradication of malaria globally," Moonen said. WHO says India accounts for 70% of the malaria cases in the Southeast Asia region.